Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally (PO) twice daily (TID) on days 1-5 and 8-12 and trametinib PO once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.